ClinicalTrials.gg
RecruitingNCT05540587ERTEMISUpdated Sep 14, 2022

Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis

A Phase 2 interventional study of Edoxaban and Warfarin in Mitral Valve Stenosis, Atrial Fibrillation and Stroke, sponsored by Sung-Hwan Kim. Recruiting at 7 sites in Korea, Republic of. Open to participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2022-09-14.

Sponsored by Sung-Hwan Kim · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 6 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled May 2022, registered Sep 2022).
  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
19 Years to 79 Years
Sex
All
01

Study summary

This study aims to compare the efficacy and safety of the edoxaban and the warfarin in atrial fibrillation patients with mitral stenosis.

The study design is a multicenter, randomized, open-label, investigator initiated phase 2 trial. The patients were randomly assigned to Edoxaban or Warfarin groups. Primary outcome was a composite of stroke and systemic arterial thromboembolism. The safety outcome was major bleeding.

Read the detailed description

Non-vitamin K antagonist oral anticoagulants (NOACs) are generally recommended as 1st line therapy for oral anticoagulant in patients with atrial fibrillation (AF). But, the efficacy and safety of NOAC in AF patients with prosthetic mechanical heart valves or moderate to severe mitral valve stenosis have not been proven, and the guidelines recommend vitamin K antagonist (VKA) administration to those patient groups. This trial aims to compare the efficacy and safety of the edoxaban and the warfarin in AF patients with moderate to severe mitral valve stenosis.

Edoxaban in patients with aTrial fibrillation and MItral Stenosis (ERTEMIS) trial is a multicenter, randomized, open-label, investigator initiated phase 2 trial. The patients were randomly assigned to Edoxaban or Warfarin groups. The primary efficacy outcome is a composite of stroke and systemic arterial thromboembolism. The secondary efficacy outcomes are each component of the primary efficacy outcomes and death from any cause. The safety outcome was major bleeding.

02

Conditions studied

  • Mitral Valve Stenosis
  • Atrial Fibrillation
  • Stroke
  • Systemic Embolism

Keywords

  • Edoxaban
  • Warfarin
  • Stroke
  • Systemic embolism
  • Mitral Valve Stenosis
  • Atrial Fibrillation
03

In context

Mitral Valve Stenosis

63 studies on the registry are indexed under Mitral Valve Stenosis; 23 are open to participants now.

This study's planned enrollment of 240 is above the median of 66 across 35 interventional studies indexed under Mitral Valve Stenosis.

Browse Mitral Valve Stenosis studies →

Lead sponsor

This is the only study on the registry with Sung-Hwan Kim as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 \< Age \< 80

    • AF diagnosed by at any time prior to enrollment
    • Moderate or severe mitral valve stenosis diagnosed by echocardiography at any time prior to enrollment

Exclusion criteria

  • Refusal to consent

    • Transient AF due to reversible cause (Postoperative, ongoing systemic inflammation, thyrotoxicosis)
    • Patients undergoing mechanical valve replacement
    • Coagulopathy
    • Hepatic impairment with significant bleeding risk
    • High bleeding risk due to following disease or condition diagnosed within 1 month prior to randomization

      • GI ulcer or bleeding, Esophageal or gastric varix, , Brain or cord injury, Surgery for brain, spinal cord, opthalmic, Intracranial hemorrhage, Arteriovenous malformation, Vascular aneurysms, Brain or spinal vascular disorder
    • Stroke, Systemic arterial thromboembolism, Acute myocardial infarction diagnosed within 14 days prior to randomization
    • End stage kidney disease (CrCL \< 15mL/min) or Dialysis
    • Severe hypertension
    • Alcohol abuse or other psychiatric disease
    • Epidural puncture or anesthesia
    • Pulmonary thromboembolism with hemodynamical instability requiring thrombolysis or thrombectomy
    • Pregnant or lactating women
    • Allergy to edoxaban or warfarin
    • Ongoing need for other anticoagulant or clarithromycin, rifampin)
    • Participants for other trials within 1 month prior to enrollment
    • Other patients to be inappropriate to participate in the trial determined by the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Edoxaban

    Patients in the Edoxaban group take Edoxaban 60mg once daily. If any of the following conditions are present, take 30mg once daily. * CrCl 15-50mL/min * Body weight ≤ 60kg * Concomitant use of P-glycoprotein inhibitor (Dronearone, Ciclosporine, Erythromycin or Ketoconazole)

    Drug: Edoxaban

  • Active comparator
    Warfarin

    Patients in the Warfarin group take Warfarin 2-10mg once daily, dose adjusted with the target INR 2-3. In the elderly or frail patients, a lower dose administration is allowed at the discretion of the investigator.

    Drug: Warfarin

Interventions

  • Patients in the Edoxaban group take Edoxaban 60mg once daily. If any of the following conditions are present, take 30mg once daily. * CrCl 15-50mL/min * Body weight ≤ 60kg * Concomitant use of P-glycoprotein inhibitor (Dronearone, Ciclosporine, Erythromycin or Ketoconazole)

  • Patients in the Warfarin group take Warfarin 2-10mg once daily, dose adjusted with the target INR 2-3. In the elderly or frail patients, a lower dose administration is allowed at the discretion of the investigator.

06

What researchers measure

Primary outcomes

  1. Composite of Stroke or Systemic arterial thromboembolism

    The number of patients with the first occurrence of a stroke or systemic embolism during the study period

    Time frame: 15 days after randomization

Secondary outcomes

  1. Stroke

    The number of patients with the first occurrence of a stroke during the study period

    Time frame: 15 days after randomization

  2. Systemic embolism

    The number of patients with the first occurrence of a systemic embolism during the study period

    Time frame: 15 days after randomization

  3. Death from any cause

    The number of patients who died for any reason during the study period

    Time frame: 15 days after randomization

07

Study locations

7 of 7 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2022 (actual). Primary completion is estimated for May 2024, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2022
First posted
Sep 14, 2022
StartActual
May 20, 2022
Primary completionEst.
May 20, 2024
CompletionEst.
May 20, 2026
Last update
Sep 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05540587
Lead sponsor
Sung-Hwan Kim
Collaborators
Daiichi Sankyo Korea Co., Ltd.
Responsible party
Sung-Hwan Kim (Professor, Seoul St. Mary's Hospital) — Sponsor-investigator
First posted
Sep 14, 2022
Start date
May 20, 2022
Primary completion
May 20, 2024 (estimated)
Completion
May 20, 2026 (estimated)
Last update
Sep 14, 2022

Study contacts

Sung hwan Kim, MD, PhD
Contact
sunghwan@catholic.ac.kr
82-2-2258-6071

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edoxaban

Start the discussion